Insmed (INSM) Competitors $73.15 -0.66 (-0.89%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends INSM vs. LEGN, ARNA, TGTX, FTSV, CCXI, TAK, ALNY, TEVA, BGNE, and UTHRShould you be buying Insmed stock or one of its competitors? The main competitors of Insmed include Legend Biotech (LEGN), Arena Pharmaceuticals (ARNA), TG Therapeutics (TGTX), Forty Seven (FTSV), ChemoCentryx (CCXI), Takeda Pharmaceutical (TAK), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), and United Therapeutics (UTHR). These companies are all part of the "medical" sector. Insmed vs. Legend Biotech Arena Pharmaceuticals TG Therapeutics Forty Seven ChemoCentryx Takeda Pharmaceutical Alnylam Pharmaceuticals Teva Pharmaceutical Industries BeiGene United Therapeutics Legend Biotech (NASDAQ:LEGN) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, community ranking, institutional ownership, valuation, risk, analyst recommendations and earnings. Is LEGN or INSM more profitable? Legend Biotech has a net margin of -66.92% compared to Insmed's net margin of -252.01%. Insmed's return on equity of 0.00% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Legend Biotech-66.92% -29.69% -19.45% Insmed -252.01%N/A -54.43% Which has better valuation & earnings, LEGN or INSM? Legend Biotech has higher earnings, but lower revenue than Insmed. Legend Biotech is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLegend Biotech$285.14M26.17-$518.25M-$0.95-43.09Insmed$305.21M42.88-$749.57M-$5.55-13.18 Does the MarketBeat Community prefer LEGN or INSM? Insmed received 462 more outperform votes than Legend Biotech when rated by MarketBeat users. However, 70.80% of users gave Legend Biotech an outperform vote while only 66.26% of users gave Insmed an outperform vote. CompanyUnderperformOutperformLegend BiotechOutperform Votes8070.80% Underperform Votes3329.20% InsmedOutperform Votes54266.26% Underperform Votes27633.74% Do institutionals and insiders believe in LEGN or INSM? 70.9% of Legend Biotech shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 4.6% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate LEGN or INSM? Legend Biotech currently has a consensus price target of $81.46, indicating a potential upside of 98.98%. Insmed has a consensus price target of $83.67, indicating a potential upside of 14.38%. Given Legend Biotech's higher probable upside, equities analysts clearly believe Legend Biotech is more favorable than Insmed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Legend Biotech 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00Insmed 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, LEGN or INSM? Legend Biotech has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, Insmed has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Does the media refer more to LEGN or INSM? In the previous week, Legend Biotech had 1 more articles in the media than Insmed. MarketBeat recorded 15 mentions for Legend Biotech and 14 mentions for Insmed. Insmed's average media sentiment score of 0.98 beat Legend Biotech's score of -0.03 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Insmed 9 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryInsmed beats Legend Biotech on 9 of the 17 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INSM vs. The Competition Export to ExcelMetricInsmedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.09B$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-13.1811.10105.1417.83Price / Sales42.88362.031,233.15158.41Price / CashN/A52.5940.4136.29Price / Book27.0910.377.096.50Net Income-$749.57M$153.60M$119.65M$226.22M7 Day Performance10.35%4.60%2.25%4.03%1 Month Performance1.68%-6.29%-2.33%4.92%1 Year Performance208.26%33.41%33.98%29.30% Insmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INSMInsmed4.089 of 5 stars$73.15-0.9%$83.67+14.4%+208.3%$13.09B$305.21M-13.18373Analyst ForecastNews CoverageLEGNLegend Biotech1.4505 of 5 stars$39.75-1.0%$81.46+104.9%-31.9%$7.25B$285.14M0.001,800ARNAArena PharmaceuticalsN/A$99.99flatN/A+0.0%$6.17B$50,000.00-9.87448TGTXTG Therapeutics3.6266 of 5 stars$34.74+11.5%$37.67+8.4%+176.8%$5.41B$233.66M-347.37290Positive NewsFTSVForty SevenN/A$95.51flatN/AN/A$4.60B$15.68M-40.8257CCXIChemoCentryx0.7411 of 5 stars$51.99flatN/A+0.0%$3.71B$32.22M-27.51178Analyst ForecastTAKTakeda Pharmaceutical3.7212 of 5 stars$13.33+0.3%N/A-4.4%$42.41B$28.20B22.9149,281High Trading VolumeALNYAlnylam Pharmaceuticals4.4235 of 5 stars$247.05-0.7%$298.09+20.7%+50.3%$31.86B$1.83B-94.292,100Analyst ForecastTEVATeva Pharmaceutical Industries3.004 of 5 stars$17.08+0.3%$19.67+15.1%+81.0%$19.35B$15.85B-20.0337,851Insider TradeBGNEBeiGene3.1896 of 5 stars$194.56+0.2%$247.07+27.0%+4.2%$18.95B$2.46B-23.5810,600Analyst DowngradeUTHRUnited Therapeutics4.5326 of 5 stars$367.36+0.8%$370.86+1.0%+61.8%$16.40B$2.33B16.131,168Insider TradeAnalyst RevisionPositive News Related Companies and Tools Related Companies Legend Biotech Competitors Arena Pharmaceuticals Competitors TG Therapeutics Competitors Forty Seven Competitors ChemoCentryx Competitors Takeda Pharmaceutical Competitors Alnylam Pharmaceuticals Competitors Teva Pharmaceutical Industries Competitors BeiGene Competitors United Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INSM) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
